Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. [electronic resource]
Producer: 20161213Description: 908-18 p. digitalISSN:- 1791-2423
- Afatinib
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor -- drug effects
- Cell Movement
- Crizotinib
- Cyclic S-Oxides -- pharmacology
- DNA Mutational Analysis
- Deoxycytidine -- analogs & derivatives
- Drug Resistance, Neoplasm
- Gene Expression Regulation, Neoplastic
- Humans
- Inhibitory Concentration 50
- Ligands
- MAP Kinase Signaling System
- Mutation
- Pancreatic Neoplasms -- metabolism
- Phenotype
- Phosphorylation
- Proto-Oncogene Proteins c-met -- metabolism
- Pyrazoles -- pharmacology
- Pyridines -- pharmacology
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- STAT3 Transcription Factor -- antagonists & inhibitors
- Signal Transduction
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.